A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg×5) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2013
At a glance
- Drugs Lamotrigine (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- 02 Aug 2013 Official title amended as reported by ClinicalTrials.gov.
- 02 Aug 2013 Planned End Date changed from 1 Aug 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 24 Jun 2013 New trial record